Please find attached herewith the un-audited financial result for the quarter and half year ended 30th September, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hindustan Agrigenetics reported unaudited results for Q2 FY26 showing profit after tax of Rs. 18.85 lakh versus Rs. 17.79 lakh in Q2 FY25. For the half-year (H1 FY26), PAT rose sharply to Rs. 59.05 lakh from Rs. 22.17 lakh in H1 FY25, a jump of about 166%. However, revenue from operations stayed near zero (Rs. 4.33 lakh for H1), and total revenue actually fell to Rs. 25.41 lakh in Q2 from Rs. 55.48 lakh a year earlier, indicating the profit is driven mainly by investment income and valuation gains, not core business activity. The balance sheet remains healthy with total equity of about Rs. 12.61 crore, cash and investments of roughly Rs. 9.34 crore, and no meaningful debt. The statutory auditor issued an unqualified limited review report.
Short-term investors may see the headline PAT growth as positive, but the sharp revenue decline and lack of operating business suggest the stock is driven by treasury and investment activity rather than core operations. This limits the sustainability of earnings and makes the shares speculative.